Efficacy of ω-3 Polyunsaturated Fatty Acids in Patients with Lung Cancer Undergoing Radiotherapy and Chemotherapy: A Meta-Analysis. (8th July 2022)

• Record Type: Journal Article
• Authors: Tao, Xin; Zhou, Qiang; Rao, Zhiyong
• Other Names: Niu Bing Academic Editor.
• Is Part Of: International journal of clinical practice. Volume 2022(2022)
• Publication Date: 2022-07-08
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1155/2022/6564466
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract : Background . Radiotherapy and chemotherapy in patients with lung cancer can lead to a series of problems such as malnutrition and inflammatory reaction. Some studies have shown that ω -3 polyunsaturated fatty acids (PUFAs) could improve malnutrition and regulate inflammatory reaction in these patients, but no relevant meta-analysis exists. Methods . We systematically searched randomized controlled trials of ω -3 PUFAs in the adjuvant treatment of lung cancer in the PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang databases. Relevant outcomes were extracted, and we pooled standardized mean differences (SMDs) using a random or fixed-effects model. The risk of bias was evaluated according to the Cochrane Handbook (version 15.1). The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results . A total of 7 studies were included. The SMDs (95% CI) of body weight change, albumin change, energy intake, and protein intake at the end of intervention were 1.15 (0.50, 1.80), 0.60 (0.11, 1.09), 0.39 (−0.10, 0.89), and 0.27 (−0.04, 0.58), respectively. The SMDs (95% CI) of CRP change and TNF- α change were −3.44 (−6.15, −0.73) and −1.63 (−2.53, −0.73), respectively. Conclusions . ω -3 PUFAs can improve nutritional status and regulate indicators of inflammation in patients with lung cancer undergoing radiotherapy and chemotherapy. This study was registered in the PROSPERO (registration number: CRD42022307699 ).